Trial
NCT03638128
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Osteogenesis Imperfecta (OI)
Intervention
Denosumab
Why stopped
The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-20